-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Johnson & Johnson Income Statement
| Chart | 2021 | 2022 | 2023 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$82.58B | $78.74B | $79.99B | $85.16B |
| Cost of Revenue |
|
$28.43B | $23.40B | $24.60B | $26.55B |
| Gross Profit |
|
$54.16B | $55.34B | $55.39B | $58.61B |
| Research & Development |
|
$12.34B | $14.28B | $14.14B | $15.05B |
| Selling,General & Administrative |
|
$22.08B | $20.12B | $19.05B | $20.11B |
| Operating Expense |
|
$34.42B | $34.40B | $33.18B | $35.56B |
| Operating Income |
|
$16.95B | $20.47B | $23.19B | $23.41B |
| Net Income |
|
$14.71B | $20.88B | $17.94B | $35.15B |
Johnson & Johnson Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$25.19B | $31.61B | $22.28B | $22.93B |
| Inventories |
|
$9.34B | $10.39B | $10.27B | $11.18B |
| Total Current Assets |
|
$51.24B | $60.98B | $55.29B | $53.50B |
| Property,Plant and Equipment |
|
$18.77B | $18.96B | $17.98B | $19.90B |
| Goodwill |
|
$36.39B | $35.25B | $36.05B | $36.56B |
| Total Assets |
|
$174.89B | $182.02B | $187.38B | $167.56B |
| Total Liabilities |
|
$111.62B | $108.00B | $110.57B | $98.78B |
| Retained Earnings |
|
$113.89B | $123.06B | $128.35B | $153.84B |
| Total Shareholder Equity |
|
$63.28B | $74.02B | $76.80B | $68.77B |
| Common Stock |
|
$3.12B | $3.12B | $3.12B | $3.12B |
Johnson & Johnson Cash flow
| Chart | 2021 | 2022 | 2023 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$7.23B | $7.39B | $6.97B | $7.49B |
| Dividends Payout |
|
-$10.48B | -$11.03B | -$11.68B | -$11.77B |
| Capital Expenditures (Capex) |
|
-$3.35B | -$3.65B | -$4.01B | -$4.54B |
| Free Cash Flow (FCF) |
|
$20.19B | $19.76B | $17.19B | $18.25B |
Johnson & Johnson Profitability
| Chart | 2021 | 2022 | 2023 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$54.16B | $55.34B | $55.39B | $58.61B |
| Gross Profit Margin (%) |
|
65.58% | 70.28% | 69.25% | 68.82% |
| Operating Income |
|
$16.95B | $20.47B | $23.19B | $23.41B |
| Operating Income Margin (%) |
|
20.52% | 26.00% | 28.99% | 27.49% |
| Net Income |
|
$14.71B | $20.88B | $17.94B | $35.15B |
| Net Income Margin (%) |
|
17.82% | 26.52% | 22.43% | 41.28% |
| EBITDA |
|
$27.50B | $30.93B | $27.17B | $23.73B |
| EBITDA Margin (%) |
|
29.27% | 35.38% | 37.71% | 27.86% |
Johnson & Johnson Ratios
| Chart | 2021 | 2022 | 2023 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
23.25% | 28.20% | 23.36% | 51.11% |
| Return on Assets (ROA) |
|
8.41% | 11.47% | 9.57% | 20.98% |
| Debt to Equity |
|
55.73% | 45.60% | 51.61% | 42.65% |
| Debt to total asset |
|
20.16% | 18.54% | 21.16% | 17.51% |
| Enterprise value to revenue |
|
5.25 | 5.97 | 6.11 | 4.75 |
| Enterprise value to EBITDA |
|
15.76 | 15.21 | 17.98 | 17.05 |
| Enterprise value |
|
$433.27B | $470.24B | $488.44B | $404.57B |
| Cash to Debt |
|
66.74% | 69.36% | 53.46% | 77.70% |
| Tax Rate (%) |
|
10.81% | 7.18% | 15.44% | 11.53% |
| Payout Ratio |
|
71.23% | 52.84% | 65.11% | 33.48% |
